Evelo Biosciences, Inc. (EVLO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 69.43 Million USD | -12.34% |
| 2021 | 79.2 Million USD | 31.67% |
| 2020 | 60.15 Million USD | 95.79% |
| 2019 | 30.72 Million USD | 34.06% |
| 2018 | 22.91 Million USD | 59.32% |
| 2017 | 14.38 Million USD | 10.28% |
| 2016 | 13.04 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 66.94 Million USD | -3.48% |
| 2023 Q1 | 69.35 Million USD | -0.11% |
| 2023 Q3 | 47.33 Million USD | -29.29% |
| 2022 Q3 | 77 Million USD | 0.98% |
| 2022 Q2 | 76.25 Million USD | 0.83% |
| 2022 Q1 | 75.62 Million USD | -4.52% |
| 2022 FY | 69.43 Million USD | -12.34% |
| 2022 Q4 | 69.43 Million USD | -9.83% |
| 2021 Q4 | 79.2 Million USD | -5.01% |
| 2021 Q1 | 65.2 Million USD | 8.39% |
| 2021 Q2 | 82.96 Million USD | 27.24% |
| 2021 FY | 79.2 Million USD | 31.67% |
| 2021 Q3 | 83.38 Million USD | 0.5% |
| 2020 Q4 | 60.15 Million USD | 10.56% |
| 2020 Q2 | 44.69 Million USD | 2.05% |
| 2020 FY | 60.15 Million USD | 95.79% |
| 2020 Q1 | 43.8 Million USD | 42.57% |
| 2020 Q3 | 54.4 Million USD | 21.72% |
| 2019 Q2 | 26.12 Million USD | 13.31% |
| 2019 FY | 30.72 Million USD | 34.06% |
| 2019 Q4 | 30.72 Million USD | 0.42% |
| 2019 Q3 | 30.59 Million USD | 17.13% |
| 2019 Q1 | 23.05 Million USD | 0.58% |
| 2018 Q3 | 24.84 Million USD | 6.91% |
| 2018 FY | 22.91 Million USD | 59.32% |
| 2018 Q4 | 22.91 Million USD | -7.76% |
| 2018 Q2 | 23.24 Million USD | 10.35% |
| 2018 Q1 | 21.06 Million USD | 46.4% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | 14.38 Million USD | 0.0% |
| 2017 FY | 14.38 Million USD | 10.28% |
| 2016 FY | 13.04 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -1339.036% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -2822.264% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -78.367% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 47.651% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -2398.489% |
| Better Therapeutics, Inc. | 23.84 Million USD | -191.221% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -738.158% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -596.126% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -163.613% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -118.46% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | -773.856% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -44.318% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 55.867% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -1880.43% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -226.133% |
| Molecular Templates, Inc. | 31.17 Million USD | -122.749% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -454.802% |
| NexImmune, Inc. | 5.08 Million USD | -1265.654% |
| Orgenesis Inc. | 35.53 Million USD | -95.393% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -320.5% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -25962.069% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -2924.965% |
| Scopus BioPharma Inc. | 7.45 Million USD | -831.432% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 85.959% |
| Statera Biopharma, Inc. | 22.67 Million USD | -206.19% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -536.183% |
| Trevena, Inc. | 48.26 Million USD | -43.867% |
| Vaxxinity, Inc. | 30.94 Million USD | -124.383% |
| Vaccinex, Inc. | 5.94 Million USD | -1068.512% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -3427.496% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -80.942% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -2414.269% |